Histone Deacetylase Inhibitors Market

Global Histone Deacetylase Inhibitors Market Size (2023 to 2028)

As per our research report, the size of the global histone deacetylase inhibitors market is predicted to be worth USD 164 Million by 2028 from USD 111 million in 2023, growing at a CAGR of 8.11% from 2023 to 2028.

Histone Deacetylase Inhibitors are classified into products such as DEAE-Dextron, calcium phosphate, Activated dendrimers, etc., and the equipment-liposomes, microinjection, and laserfection. HDACs play an important role in the regulation of gene expression. HDACs are present in a high amount in many types of tumors.

MARKET DRIVERS:

The adoption of innovative technology advancements, improvements in the healthcare infrastructure, and the rapid growth rate in government initiatives in pharmaceutical & biotechnology companies for the drug developments greatly influence the global histone deacetylase inhibitors market growth.

Collaborations between the companies & lunch innovative products are increasing the growth of the market. An increase in cancer patients and other illnesses with effective results in treatment is driving the market of HDAC market. Investment in research and development activities surges the market. HDAC reduces the rate of angiogenesis & increases the immune response, providing scope for market growth.

A growing number of people suffering from cancer is a crucial factor propelling the market demand. Increasing support from the government and the rise in investments in research and development in the cancer treatment field drive the demand of the market. Huge demand for achieving maximum productivity at a very less cost is the major factor responsible for boosting up market growth. The manufacturers of histone deacetylase inhibitors collaborate with other companies, which is also one of the factors leading to market growth. 

Need to make better changes in the effectiveness of new treatments, growing mergers and collaborations also accelerate market growth. The rise in the common increase of cancer is also bolstering the market. Also, research and development related to disorders of nerves and other diseases are driving the market forward. Funds from the government and other organizations are also boosting the market. Pharmaceutical industries spending huge amounts of money on R&D and the growing prevalence of diagnosing the disease at an early stage are ascribed to bolster the market's growth rate. 

MARKET RESTRAINTS:

The lack of reimbursement policies in undeveloped countries is hindering the global Histone deacetylase inhibitors market growth.

A lack of knowledge among people may limit the growth rate of this market. Strict rules and guidelines to be followed for the product to be approved are also the factors that restrain the market growth. Less awareness among patients of the treatment of cancer & chronic diseases is hampering the market growth. The rising value of raw materials required for the production & manufacturing of HDACs has reduced the market growth for the future. HDACs' side effects such as toxicity after consumption are also a factor impeding the demand of the market. Some factors that influence the HDACs market are less skilled professionals in well-developed countries.

Impact of COVID-19 on the global histone deacetylase inhibitors market:

The novel coronavirus (COVID 19) has strained severe health risks to humans and the economy. By March 2020, the virus has spread to every country across the globe. In general, HDAC inhibitors are used by kidney and diabetic patients to fight disease-causing cells. The use of an HDAC inhibitor, romidepsin, effectively stops the virus from entering the body. The U.S. Food and Drug Administration (FDA) approves HDAC inhibitors treatment for pulmonary fibrosis and essential molecular mechanisms in executing the pathological procedures in recovered COVID-19 patients. Panobinostat is one HDAC inhibitor that can act as a preventive drug against COVID-19. HDAC presents one of the most promising viral drugs used in treating infectious viruses. As of now, six HDAC anticancer drugs were approved by the FDA. In the current situation, the EMA-approved SARS-CoV-2 off-labeled HDAC inhibitor drugs are reused to restrain or avoid host-virus interaction. HDAC valproic acid is available for treating those who are diagnosed with epilepsy. The drug is remodeled for patients with COVID-19 to avoid acute respiratory distress syndrome (ARDS). Valproic acid helps both COVID-19 infection and in those who are infected decreases the ARDS along with other aimed organ damage, reducing hospitalizations and death. 

REPORT COVERAGE:

This market research report on Global Histone Deacetylase Inhibitors Market has been segmented based on class, application, and region.

Histone Deacetylase Inhibitors Market - By Class:

• Class I HDACs
• Class II HDACs
• Class III HDACs

Histone Deacetylase Inhibitors Market – By Application:

• Cancer
• Central Nervous System Disorders

Histone Deacetylase Inhibitors Market – By Region:

• North America
• Europe
• Asia-Pacific
• Latin America
• The Middle East and Africa

Geographically, the North American regional market accounted for the largest share of the global market. It is expected to retain its lead by 2028. Higher adoption rates in this region are the cause attributable to the observable trend mentioned above. Europe comes second by market share. It is, however, anticipated to experience slow growth in the forecast period. 

Europe stands second, followed by North America. This region is likely to have a high CAGR value during the period and is estimated to reach a million-dollar USD. In the European region, the UK is expected to lead the market. The adoption of advanced technology in healthcare centers is propelling the demand of the market.

The Asia Pacific is poised for a robust growth trajectory in the forecast period. China will spearhead this growth spurt. Latin America and MEA continue to tail these leading regional markets in the forecast period.

KEY MARKET PARTICIPANTS:

Some of the notable companies leading the global histone deacetylase inhibitors market profiled in the report are Merck & Co., Inc., Celgene Corporation, Eisai Pharmaceuticals, Novartis, Acetylon Pharmaceuticals, Celeron Therapeutics, Envivo Pharmaceuticals, and Pfizer, Inc.

RECENT MARKET DEVELOPMENTS:

• On November 29, 2019, the Shenzhen Chipscreen Biosciences Company. Ltd. launched an innovative product named Epidaza (Chidamide), it's an oral subtype of histone deacetylase inhibitors. This product is used for the treatment of HER2- advanced negative breast cancer. Shenzhen had received approval from the National Medical Products Administration.
• On November 19, 2019, Alkermes, the Irish biopharmaceutical company,, announced Rodin Therapeutic's acquisition of worth US $ 950 million. Rodin Therapeutics developed the small molecule therapy for synaptopathy. They also designed the molecules to target the histone deacetylase inhibitors. Inhibition decreases the toxicity of haematologic safety.